Big Pharma Stock Forward View - 20 Period Moving Average
| PRM Stock | CAD 14.03 -0.37 -2.57% |
This page documents 20 Period Moving Average forecast output for Big Pharma Split as reference data. The model is applied to historical closing prices and the resulting projection and error statistics are shown below.
The 20 Period Moving Average forecasted value of Big Pharma Split on the next trading day is expected to be 14.65 with a mean absolute deviation of 0.48 and the sum of the absolute errors of 19.84.The eieght-period moving average method has an advantage over other forecasting models in that it does smooth out peaks and valleys in a set of daily observations. Big Pharma Split 20-period moving average forecast can only be used reliably to predict one or two periods into the future. The 20 Period Moving Average reference information for Big Pharma is based on available price data and is intended for informational purposes. 20 Period Moving Average Price Forecast For the 20th of March
Given 90 days horizon, the 20 Period Moving Average forecasted value of Big Pharma Split on the next trading day is expected to be 14.65 with a mean absolute deviation of 0.48 , mean absolute percentage error of 0.29 , and the sum of the absolute errors of 19.84 .Please note that although there have been many attempts to predict Big Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Big Pharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Big Pharma | Big Pharma Price Prediction | Research Analysis |
Forecasted Value
Forecasting Big Pharma Split for the next session involves measuring the model's historical ability to define credible downside and upside scenarios. The projected forecast band currently runs from roughly 13.15 on the downside to about 16.14 on the upside.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the 20 Period Moving Average forecasting method's relative quality and the estimations of the prediction error of Big Pharma stock data series using in forecasting. Note that when a statistical model is used to represent Big Pharma stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 80.1191 |
| Bias | Arithmetic mean of the errors | -0.1638 |
| MAD | Mean absolute deviation | 0.484 |
| MAPE | Mean absolute percentage error | 0.0333 |
| SAE | Sum of the absolute errors | 19.843 |
Other Forecasting Options for Big Pharma
Any investor evaluating Big must grapple with the challenge of interpreting Big Pharma's price movement accurately. Big Stock price charts typically contain substantial noise that can complicate analysis and lead to poor decisions.Big Pharma Related Equities
The following equities are related to Big Pharma within the Financials space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Big Pharma against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Big Pharma Market Strength Events
Market strength indicators for Big Pharma assess how the stock responds to ongoing changes in market conditions and investor sentiment. By monitoring these indicators, investors can identify the most opportune moments to trade Big Pharma Split.
Big Pharma Risk Indicators
Risk indicator analysis for Big Pharma is a critical component of accurate price forecasting and sound investment decision-making. By identifying how much risk is embedded in Big Pharma's investment, investors can decide how to position and protect their exposure.
| Mean Deviation | 1.14 | |||
| Semi Deviation | 1.42 | |||
| Standard Deviation | 1.62 | |||
| Variance | 2.64 | |||
| Downside Variance | 3.73 | |||
| Semi Variance | 2.02 | |||
| Expected Short fall | -1.30 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Big Pharma
A coverage review of Big Pharma Split helps investors see when the security is attracting above-average attention from contributors and market observers. A disciplined read of coverage helps investors separate durable relevance from temporary noise.
Other Macroaxis Stories
Macroaxis publishes story content for a diverse readership that includes finance students, independent investors, money managers, and market-focused operating teams. What connects that audience is a focus on building stronger portfolios through better research, risk awareness, and comparative analysis.
Story Categories
Currently Trending Categories
Big Pharma Short Properties
A short-interest review of Big Pharma Split helps investors understand whether skepticism in the market is becoming more influential. The practical goal is to identify when the balance between long and short participation may be changing the quality of the setup.
| Common Stock Shares Outstanding | 1.1 M | |
| Cash And Short Term Investments | 26.2 M |
More Resources for Big Stock Analysis
Other Information on Investing in Big Stock
Financial ratios for Big Pharma provide valuation context across profits, cash flow, and enterprise value. They help compare Big across valuation measures and peers.